@docrodwong: a standing ovation for daraxonrasib at asco. over 40k oncologists, entrepreneurs, investors, and patient advocates toge…
Summary
Daraxonrasib received a standing ovation at ASCO as Revolution Medicines' breakthrough against pancreatic cancer, celebrated by over 40,000 oncologists, entrepreneurs, investors, and patient advocates.
View Cached Full Text
Cached at: 06/01/26, 01:25 AM
a standing ovation for daraxonrasib at asco. over 40k oncologists, entrepreneurs, investors, and patient advocates together celebrating revmed’s breakthru in the fight against pancreatic cancer. u never forget these moments. it’s what innovation is all about. https://t.co/lscwBZJL0N
Similar Articles
@ScienceMagazine: Drug candidates that form covalent bonds with their targets were historically avoided because of toxicity concerns. How…
A new Science study reports streamlined access to an underexplored covalent warhead type with well-tempered reactivity, enabling practical use in drug discovery.
Which area of healthcare will benefit most from AI in the next few years?
Discussion on which area of healthcare will see the biggest transformation from AI in the next few years, including diagnosis, drug discovery, patient monitoring, and medical imaging.
Closing the data loop in AI-driven drug discovery
AI accelerates drug discovery by predicting candidates and reducing costs, but success depends on high-quality data and integration with lab systems to close the data loop and validate predictions.
@Tsinghua_Uni: Breaking records across all four key benchmarks! Innovative Tsinghua's @AIRTHU1201 and collaborators have unveiled Gala…
Tsinghua University and AIRTHU introduce GalaxyVS, a method that transforms protein–ligand docking into ultra-large-scale parallel vector retrieval, setting a new global benchmark for high-throughput drug discovery.
TriGlue: a Biology-Inspired Generative Model for Generating Molecular Glue-Induced Ternary Complex
TriGlue is a biology-inspired generative model that designs molecular glue-induced ternary complexes by first predicting protein-protein interfaces and then generating molecular glues conditioned on the interface, enabling targeted protein degradation.